Atebimetinib (IMM-1-104) is an orally active, deeply periodic MEK inhibitor that directly targets MEK and chronically suppresses MAPK signaling. It is intended for combination therapy in metastatic pancreatic cancer and non-small cell lung cancer (NSCLC).
Molecular Weight:
506.55
Purity:
99.14%
CAS Number:
[2669009-92-9]
Formula:
C23H27FN4O6S
Target:
MEK
T206215
* VAT and and shipping costs not included. Errors and price changes excepted